Comparison of Two Basal Insulin Therapies for Patients With Type 1 Diabetes

Eli Lilly and Company387 enrolled

Overview

The purpose of this study is to examine the efficacy and safety of insulin lispro protamine suspension (ILPS) as compared to insulin detemir as basal insulin combined with mealtime insulin therapy in patients with type 1 diabetes. A gatekeeper strategy will be employed for sequentially testing the secondary objectives.

Phase 3b, randomized, multicenter, multinational, open-label, two-arm, active control, parallel study to determine safety, efficacy, and noninferiority of basal analog insulin lispro protamine suspension (ILPS, also referred to as NPL \[neutral protamine Hagedorn\]), injected two times a day, compared with basal analog insulin detemir, injected two times a day, as measured by change in hemoglobin A1c (HbA1c) from baseline (Visit 2) to 32 weeks in adult patients with type 1 diabetes when used in combination with bolus insulin lispro, injected three times a day.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

387

Conditions

Diabetes Mellitus, Type 1

Interventions

Insulin Lispro Protamine SuspensionDRUG

Patient specific dose, twice daily (BID), within 15 minutes before meals, subcutaneous (SC) injection x 32 weeks.

Insulin LevemirDRUG

Patient specific dose insulin Levemir (detemir) twice daily (BID) subcutaneous (SC) injection x 32 weeks

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Clinical diagnosis of type 1 diabetes for one year or more * Age 18 years or older * Body mass index (BMI) less than or equal to 35 kilograms per square meter (kg/m2) * Have a hemoglobin A1c (HbA1c) 1.2 to 2.0 times the upper limit of the normal (ULN) reference range within 30 days prior to Visit 1 or collected and analyzed at a local laboratory at Visit 1 * As determined by the investigator, are capable and willing to do the following: * perform self monitoring of blood glucose (SMBG), * complete patient diaries as required for this protocol, * use the insulin injection device(s) according to the instructions provided, * are receptive to diabetes education, * comply with the required study visits. Exclusion Criteria: * Have taken any oral antihyperglycemic medications (OAMs) within 3 months prior to Visit 1. * Have had more than one episode of severe hypoglycemia, as defined in the Abbreviations and Definitions section of the protocol, within 6 months prior to entry into the study * Are pregnant or intend to become pregnant during the course of the study or are sexually active women of childbearing potential not actively practicing birth control by a method determined by the investigator to be medically acceptable or women who are breastfeeding * Are receiving chronic (lasting longer than 14 consecutive days) systemic glucocorticoid therapy (excluding topical, intra-articular, intraocular, and inhaled preparations) or have received such therapy within the 4 weeks immediately preceding Visit 1. * Have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry.

Locations (28)

Outcomes

Primary Outcomes

Change in Hemoglobin A1c (HbA1c) From Baseline to Endpoint

Time frame: baseline and 32 weeks

Secondary Outcomes

Actual and Change From Baseline Hemoglobin A1c (HbA1c) Values

The summary statistics represents the mean of all subjects. Change from baseline is calculated for each individual subject for the specific visit and then the "mean change from baseline" is calculated by averaging out for all subjects. \[Sum over all (i) {A1c at Week 8 for Subject(i) minus A1c Baseline for Subject (i)}/Total Subjects\]. Therefore, for example, the Change from Baseline is not equal to the difference of Mean A1c for Week 8 minus Mean A1c for baseline.

Time frame: Baseline, 8,16, 24, 32 Weeks

Percentage of Patients With Hemoglobin A1c (HbA1c) Less Than or Equal to 7.0% and HbA1c Less Than or Equal to 6.5%

Time frame: 32 Weeks

7-Point Self-Monitored Blood Glucose (SMBG) at Endpoint

Actual daily mean blood glucose levels at endpoint. The SMBG excursion is the difference between the postprandial and preprandial blood glucose concentration taken at the morning, midday and evening meals.

Time frame: 32 Weeks

Glycemic Variability at Endpoint

Glycemic variability was measured by standard deviation (SD) value of fasting blood glucose as measured by intra-patient glycemic variability (determined by the 7-point self-monitored blood glucose \[SMBG\] profiles at endpoint); mean value (M-value), which was the mean of the intra-days self-monitored blood glucose values, and by the mean of daily difference (MODD), which was the mean of the between-days self-monitored blood glucose values.

Time frame: 32 Weeks

Number of Self-Reported Hypoglycemic Episodes (Including Nocturnal, Non-Nocturnal, and Severe Hypoglycemia) Overall and at Endpoint

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Idaho Falls, Idaho, United States

Springfield, Illinois, United States

Topeka, Kansas, United States

San Antonio, Texas, United States

Buenos Aires, Argentina

La Plata, Argentina

Wollongong, New South Wales, Australia

Box Hill, Victoria, Australia

Fortaleza, Brazil

São Paulo, Brazil

...and 18 more locations